- Tumors1000+
- Cancer1000+
- Pathologic Processes1000+
- Pathology1000+
- Nervous System Diseases1000+
Any
<10 miles
<30 miles
<50 miles
<70 miles
Filter Results
Condition
- Tumors1000+
- Cancer1000+
- Pathologic Processes1000+
- Pathology1000+
- Nervous System Diseases1000+
Where are you looking?
How far are you willing to travel?Any
How old are you?
Trial Status
Recruiting statusPlacebo
Recruiting
Waitlist Available
Administration Type
Trial Phase
Biomarkers
Stage of Disease
- HER2 negative
- ER positive
- HER2 positive
- PD-L1 positive
- PR positive
- EGFR positive
- PR negative
- ER negative
- KRAS positive
- PD-L1 negative
- EGFR negative
- p16 positive
- BRAF positive
- ALK negative
- HLA-A positive
- CD20 positive
- IDH positive
- BRCA1 positive
- BRCA2 positive
- CD19 positive
- ALK positive
- HLA positive
- MET positive
- IDH negative
- p16 negative
- ROS1 positive
- MSI-H positive
- HR positive
- ROS1 negative
- HLA negative
- HPV positive
- MYC positive
- NRAS positive
- PALB2 positive
- TP53 positive
- dMMR positive
- RB1 negative
- BRAF negative
- HLA-A negative
- RB1 positive
- BRCA positive
- PIK3CA positive
- FLT3 positive
- HPV negative
- NF1 positive
- RET positive
- ATM positive
- MET negative
- NTRK positive
- ANA positive
- CD22 positive
- KIT positive
- KRAS negative
- MGMT negative
- MMR positive
- RAS positive
- anti-dsDNA positive
- ARID1A positive
- BCL2 positive
- CCND1 positive
- HRAS positive
- RAD51 positive
- BRIP1 positive
- CHEK2 positive
- HbSS positive
- MGMT positive
- BCL6 positive
- BCR-ABL1 positive
- CD123 positive
- CD30 positive
- CFTR positive
- MLH1 positive
- MSH6 positive
- PD-1 positive
- PMS2 positive
- Philadelphia chromosome positive
- RAS negative
- MMR negative
- MSH2 positive
- PTEN positive
- RET negative
- TP53 negative
- anti-Sm positive
- AR positive
- FANCA positive
- HBsAg positive
- MSI negative
- ctDNA positive
- p53 positive
- CDK4 positive
- FGFR2 positive
- HBV DNA negative
- HBV DNA positive
- HBsAg negative
- HPV16 positive
- HR negative
- MSI positive
- MSS positive
- NPM1 positive
- NRAS negative
- NTRK1 positive
- PD-1 negative
- RAD51C positive
- t(11;14) positive
- ABCA4 positive
- BAP1 positive
- BARD1 positive
- BCR-ABL positive
- BRCA negative
- BRCA1 negative
- BRCA2 negative
- CD33 positive
- CDK12 positive
- DLL3 positive
- DMD positive
- Del(17p) positive
- FGFR3 positive
- FLT3 negative
- GRN positive
- Ki-67 positive
- MECP2 positive
- MSI-H negative
- MSS negative
- MTAP positive
- NF2 positive
- NTRK negative
- PDGFRA positive
- RAD51D positive
- RAD54L positive
- RF positive
- SMARCA4 positive
- SMN1 positive
- TERT positive
- TROP2 positive
- ZnT8 positive
- dMMR negative
- AKT1 positive
- APC positive
- APOL1 positive
- ASXL1 positive
- CCNE1 positive
- CD3 positive
- CD5 positive
- CDK6 positive
- CHEK1 positive
- CLDN18.2 positive
- COL7A1 positive
- Complex karyotype positive
- FANCL positive
- FGFR positive
- FMR1 positive
- GPC3 positive
- HBB positive
- HBcAb negative
- HbSC positive
- HbSβ0-thalassemia positive
- IA-2 positive
- KMT2A positive
- MLH1 negative
- MSH2 negative
- MSH6 negative
- NBN positive
- PMS2 negative
- Ph positive
- RAF positive
- STK11 positive
- TROP2 negative
- t(14;16) positive
- t(4;14) positive
- t(9;22) positive
- AChR positive
- AKT negative
- ATR positive
- Anti-PLA2R positive
- C5 positive
- CA-125 positive
- CCND2 positive
- CCND3 positive
- CD19 negative
- CD4 count positive
- CD4 positive
- CD70 positive
- CD8 positive
- CTNNB1 positive
- DMPK positive
- DNMT3A positive
- EBV positive
- EpCAM positive
- Ex19del positive
- FANCD2 positive
- FOLR1 positive
- FRα positive
- HBcAb positive
- HCV RNA positive
- HRD positive
- IA-2A positive
- IAA positive
- ICA positive
- IL2RG positive
- JAK2 positive
- Gleason Score 10
- Gleason Score 6
- Gleason Score 7
- Gleason Score 8
- Gleason Score 9
- Grade 1
- Grade 2
- Grade 3
- Grade 4
- Stage IV
- Stage III
- Stage II
- Stage I
- 1927nm Fractional Thulium Laser Treatment
- Adalimumab
- Adjuvant Chemotherapy without Concurrent Biologic/Targeted Therapy
- Adjuvant Therapy (except reconstruction)
- Allogeneic Hematopoietic Cell Transplantation
- Alopecia from Prior Anti-Cancer Therapy
- Alopecia from Prior Treatment
- Anemia from Prior Anti-Cancer Therapy
- Anti-EGFR Therapy (Cetuximab or Panitumumab)
- Anti-EGFR Therapy (Cetuximab or Panitumumab) for at least 16 weeks with CR or PR
Trial Status
Recruiting statusPlacebo
Recruiting
Waitlist Available
Administration Type
Trial Phase
Biomarkers
Stage of Disease
9565 trials
Kingman, KS (<20 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing giredestrant, a medication given after initial treatment to prevent breast cancer from returning. It focuses on patients with a specific type of early-stage breast cancer that is hormone-driven and at higher risk of recurrence. Giredestrant works by blocking the hormone estrogen from helping cancer cells grow. Giredestrant has shown promise in previous studies.
Efficacy & Safety Awards
Pivotal Trial
No Placebo-Only Group
Kingman, KS (<20 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a 4-drug combo vs. a 3-drug combo to see if the former is more effective in shrinking cancer or preventing its return.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Kingman, KS (<20 mi)
Recruiting
Phase 2 & 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial tests two drugs, MRTX849 and pembrolizumab, in patients with advanced lung cancer who have a specific genetic mutation. MRTX849 targets the mutation to stop cancer growth, while pembrolizumab boosts the immune system to fight the cancer. The study aims to see how well these treatments work alone and together.
Efficacy & Safety Awards
No Placebo-Only Group
Local Institution - 007-942-F
TreatmentsPhase 3 comparator arm (Chemotherapy)MRTX849 (Small Molecule Drug)Adagrasib (Small Molecule Drug)Pembrolizumab (Checkpoint Inhibitor)
Sponsors and Investigators
Mirati Therapeutics Inc.
Richard Chao, MD, Richard L Chao, MD, Elise Horvath Walsh, MD, Barbara Wamil, MD, Bristol-Myers Squibb, Vicky Kang, MD, Viola Chen, MD
Kingman, KS (<20 mi)
Recruiting
Phase 21 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial studies four drugs to treat patients with worsening meningioma. These drugs work by blocking enzymes that the tumor cells need to grow. The trial focuses on patients whose tumors have specific genetic mutations.
Efficacy & Safety Awards
No Placebo-Only Group
Kingman, KS (<20 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial compares shorter chemo-immunotherapy without anthracyclines to usual chemo-immunotherapy to treat early-stage triple negative breast cancer. Drugs used to stop cancer cells from growing/dividing & kill them, plus an immunotherapy drug.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Kingman, KS (<20 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
Kingman, KS (<20 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial tests a combination of two drugs to see if they're better than one drug at preventing breast cancer from coming back in patients with high risk, HER2 positive breast cancer.
Efficacy & Safety Awards
Pivotal Trial
Kingman, KS (<20 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
Kingman, KS (<20 mi)
Recruiting
Phase 2 & 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial will test new targeted cancer therapies against standard of care therapy in order to find more effective treatments.
Efficacy & Safety Awards
No Placebo-Only Group
Get notified when new Cutaneous Melanoma trials are postedWe'll send you an email whenever new trials are posted
Kingman, KS (<20 mi)
Recruiting
Phase 2 & 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is studying nivolumab and ipilimumab to see how well they work with or without sargramostim in treating patients with stage III-IV melanoma that cannot be removed by surgery.
Efficacy & Safety Awards
No Placebo-Only Group
Kingman, KS (<20 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial studies crizotinib for patients with stage IB-IIIA NSCLC who have had surgery and have an ALK fusion mutation. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working.
Efficacy & Safety Awards
Pivotal Trial
No Placebo-Only Group
Wichita, KS (<50 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a medication called Pegozafermin to see if it can lower high levels of fats in the blood in people with severe hypertriglyceridemia. These patients have very high triglyceride levels, which can lead to serious health issues. The medication aims to reduce these fat levels to improve their health.
Efficacy & Safety Awards
Pivotal Trial
Wichita, KS (<50 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial will test if ubrogepant is safe and effective for young people with migraines. Ubrogepant is a medication taken by mouth to treat migraine headaches. It works by blocking a protein in the brain that causes migraine pain. The study focuses on children and adolescents who suffer from migraines.
Efficacy & Safety Awards
Pivotal Trial
Wichita, KS (<50 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing lepodisiran, a medication given as an injection under the skin. It targets people with high levels of lipoprotein(a) who have cardiovascular disease or are at risk of heart attack or stroke. The medication works by lowering lipoprotein(a) levels to reduce the risk of these cardiovascular events.
Efficacy & Safety Awards
Pivotal Trial
Hutchinson, KS (<50 mi)
Recruiting
Phase 2
0 Criteria Met
Eligibility Criteria
SummaryThis trial will test the effectiveness and safety of a drug called amlitelimab in adults with non-responsive celiac disease who are on a gluten-free diet. The study will compare amlit
Wichita, KS (<50 mi)
Recruiting
Phase 33 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing two different treatment combinations for patients with extensive-stage small cell lung cancer who have not received any prior treatment. One group will receive a new drug called Serplulimab along with standard chemotherapy, while the other group will receive an existing drug called Atezolizumab with the same chemotherapy. Both immunotherapy drugs aim to help the immune system fight cancer, and the chemotherapy drugs work by killing cancer cells. Atezolizumab has been shown to improve survival in small-cell lung cancer when combined with chemotherapy, changing the standard first-line therapy.
Efficacy & Safety Awards
Pivotal Trial
Verified Trial Data
No Placebo-Only Group
Wichita, KS (<50 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial aims to study the safety and effectiveness of a new drug called ubrogepant in treating menstrual migraines. Menstrual migraines are headaches that occur before, during, or after
Efficacy & Safety Awards
Pivotal Trial
SummaryThis trial is testing a medication called efruxifermin (EFX) to see if it can help people with a specific liver condition called non-cirrhotic NASH/MASH. The patients have significant liver damage but not cirrhosis. EFX aims to improve liver health by reducing swelling and scarring in the liver.
Efficacy & Safety Awards
Pivotal Trial
Get notified when new Nonalcoholic Steatohepatitis or Metabolic Steatohepatitis trials are postedWe'll send you an email whenever new trials are posted
SummaryThis trial is testing a medication called efruxifermin (EFX) to see if it can help people with specific liver conditions. These conditions are hard to treat with current methods. EFX aims to improve liver health by reducing inflammation and fat buildup in the liver.
Efficacy & Safety Awards
Pivotal Trial
1
2
3
…50